Editor’s Choice

Optimization of Maternal Magnesium Sulfate Administration for Fetal Neuroprotection: Application of a Prospectively Constructed Pharmacokinetic Model to the BEAM Cohort

Magnesium sulfate is indicated for neuroprotection of the fetus who is born before 32 weeks gestation.  To date, optimal dosing of magnesium sulfate in the pregnant woman has not been know.  This month’s Editor’s choice article analyzes data from the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) to develop an optimal dosing protocol for pregnant women in whom the baby will be delivered before 32 weeks gestation. The authors model suggests that magnesium serum concentrations of 3.7-4.4 mg/dL are needed to provide this protection to the baby and prevent cerebral palsy.